Approval · Notice of Compliance 29603 · 2022
MIDODRINE: Notice of Compliance 29603
Issued December 1, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29603
- Date
- December 1, 2022
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Companies
- Canadian reference product
- MIDODRINE (AA Pharma Inc.)
Products in this notice
Medicinal ingredients
- MIDODRINE HCL 2.5 MG per TAB
- MIDODRINE HCL 5 MG per TAB